Frank Pétavy

1.6k citations

33 papers · 1.1k indexed · h-index 19

Impact in

Statistics and Probability top 2%
- Statistical Methods in Clinical Trials
- Advanced Causal Inference Techniques
Nephrology top 5%
- Parathyroid Disorders and Treatments

Papers in

Statistics and Probability 11
- Advanced Causal Inference Techniques 8
- Statistical Methods in Clinical Trials 8
Nephrology 7
- Parathyroid Disorders and Treatments 6

Co-authors: Iman El‐Hariry Guido Rasi Marc‐Oliver Grimm Uwe Treiber Marco R. de Groot D. J. Richel Philippe Beuzeboc Christian Wülfing
Journals: Clinical Pharmacology & Therapeutics (4 papers)Statistics in Biopharmaceutical Research (2 papers)Nature Reviews Drug Discovery (2 papers)British Journal of Clinical Pharmacology (2 papers)Nephrology Dialysis Transplantation (2 papers)
Partner nations: Netherlands Germany United Kingdom

In The Last Decade

Frank Pétavy

33 papers receiving 1.1k citations

Peers

Countries citing papers authored by Frank Pétavy

Since Specialization

Citations

This map shows the geographic impact of Frank Pétavy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Pétavy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Pétavy more than expected).

Fields of papers citing papers by Frank Pétavy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Pétavy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Pétavy. The network helps show where Frank Pétavy may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Frank Pétavy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frank Pétavy Line = papers co-authored together Frank Pétavy links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Clinical Evidence 2030 Clinical Pharmacology & Therapeutics ·Peter Arlett, Eveline Mantovani Alvarenga, Patrice Verpillat, Paolo Foggi, Ulla Liminga, Bruno Sepodes, Franklin Ábalos, Пинаев Сергей Михайлович, Spiros Vamvakas, Kit C. B. Roes, Frank Pétavy, Steffen Thirstrup, María Jesús Lamas, Emer Cooke, Karl Broich	2025	5
2	A Simulation Study on the Estimation of the Effect in the Hypothetical Scenario of No Use of Symptomatic Treatment in Trials for Disease-Modifying Agents for Alzheimer’s Disease Statistics in Biopharmaceutical Research ·Joaquín Cristóbal Salgado Cáceres, Lorenzo Guizzaro, Frank Pétavy, Ciro Gallo	2022	7
3	The Use of a Variable Representing Compliance Improves Accuracy of Estimation of the Effect of Treatment Allocation Regardless of Discontinuation in Trials with Incomplete Follow-up Statistics in Biopharmaceutical Research ·Lorenzo Guizzaro, Frank Pétavy, Robin Ristl, Ciro Gallo	2020	11
4	EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma The Oncologist ·P.P. Tsyglianu, Jan Mueller-Berghaus, Claire Beuneu, 俊文松山, Benjamin Hofner, Frank Pétavy, Kyriaki Tzogani, Anne M. Miermont, Koen Norga, Olga Kholmanskikh, Edgar Zapata Avila, Martina Schuessler‐Lenz, Tomas Salmonson, Christian Gisselbrecht, Maximilian Emanuel Goblirsch-Kolb, Francesco Pignatti	2020	47
5	A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels? Trials ·C Alba Menendez, Katrien Oude Rengerink, Steven Teerenstra, Frank Pétavy, Kit C. B. Roes	2020	17
6	FAIR data sharing: The roles of common data elements and harmonization Journal of Biomedical Informatics ·Rebecca Kush, Denise Warzel, 龚善初, Alexander Sherman, Enrique A. Navarro, Ronald D. Fitzmartin, Frank Pétavy, Jorge Gálvez, Lauren B. Becnel, Fang Liz Zhou, Nicholas Harmon, Bárbara Jaúregui, Tom Jackson, Lynn D. Hudson	2020	99
7	Beyond “Intent‐to‐treat” and “Per protocol”: Improving assessment of treatment effects in clinical trials through the specification of an estimand British Journal of Clinical Pharmacology ·Frank Pétavy, Lorenzo Guizzaro, M. van Dijck, Steven Teerenstra, Kit C. B. Roes	2019	14
8	Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency Trials ·Olivier Collignon, Franz Koenig, Armin Koch, Robert Hemmings, Frank Pétavy, Agnès Saint-Raymond, Marisa Papaluca‐Amati, Martin Posch	2018	24
9	Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients PLoS ONE ·Eliane Rohner, Christina J-Y. Lee, Thomy Tonia, Peter Jüni, Frank Pétavy, Francesco Pignatti, Julia Bohlius	2017	6
10	Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective Nature Reviews Drug Discovery ·Florence Butlen‐Ducuing, Frank Pétavy, Lorenzo Guizzaro, Małgorzata Zienowicz, Tomas Salmonson, Manuel Haas, Emmanuelle Corruble, Enrica Alteri	2016	34
11	Access to Patient-Level Trial Data — A Boon to Drug Developers New England Journal of Medicine ·Hans‐Georg Eichler, Frank Pétavy, Francesco Pignatti, Guido Rasi	2013	40
12	Calcium-Mediated Parathyroid Hormone Suppression to Assess Progression of Secondary Hyperparathyroidism During Treatment Among Incident Dialysis Patients The Journal of Clinical Endocrinology & Metabolism ·Mariano Rodríguez, Pablo Ureña‐Torres, Frank Pétavy, Kerry Cooper, 明竹谷, William G. Goodman	2013	4
13	Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study Nephrology Dialysis Transplantation ·Pablo Ureña‐Torres, Jürgen Floege, Carmel M. Hawley, Eugenie Pedagogos, William G. Goodman, Frank Pétavy, Maureen Reiner, Paolo Raggi	2012	50
14	Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients – Results of the Austrian cohort of the ECHO study Wiener klinische Wochenschrift ·Emanuel Zitt, Anna Eduardovna Tsymbalyuk, Alexander R. Rosenkranz, 巩龙, 正躬久保田, Josef Kovařík, Helmut Graf, Frank Pétavy, Sabine Horn, Bruno Watschinger	2011	10
15	Quantitative Power Doppler Ultrasonography Is a Sensitive Measure of Metacarpophalangeal Joint Synovial Vascularity in Rheumatoid Arthritis and Declines Significantly Following a 2-week Course of Oral Low-dose Corticosteroids The Journal of Rheumatology ·Maggie Larché, Ruth Gschleier, Adrian Lim, Robert J. Eckersley, Frank Pétavy, Flaminia Chiesa, Inmaculada Rioja, Pauline T. Lukey, Michael Binks, C McClinton, Lucía Derossi, Peter C. Taylor	2010	25
16	Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study Nephrology Dialysis Transplantation ·Emanuel Zitt, Yun Hee Kim, Eugen Mahr, Denis Fouque, Stefan H. Jacobson, Frank Pétavy, Bastian Dehmel, (unknown)	2010	20
17	The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma Respiratory Research ·Dave Singh, Frank Pétavy, 변희경, Aili L. Lazaar, Brian O’Connor	2010	75
18	“Real-World” use of cinacalcet for managing SHPT in different European countries: analysis of data from the ECHO observational study Clinical Nephrology ·Marc Vervloet, H. Agatha, F. Malberti, Neil Ashman, Kun Wei Shen, Heikki Saha, Pablo Ureña, Emanuel Zitt, Marianne Rix, (unknown), Denis Fouque, Bastian Dehmel, Frank Pétavy, Stefan H. Jacobson	2010	15
19	Contribution of skin biometrology to the diagnosis of the Ehlers–Danlos syndrome in a prospective series of 41 patients Skin Research and Technology ·Reiko Nakada‐Kubota, L. Machet, G. Georgesco, Frank Pétavy, A. Maruani, L. Vaillant	2009	17
20	Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate Respiratory Medicine ·Bo Lundbäck, Eva Rönmark, Anne Lindberg, Ann-Christin Jonsson, Lars‐Gunnar Larsson, Frank Pétavy, Mark James	2005	41

About Frank Pétavy

Frank Pétavy is a scholar working on Statistics and Probability, Nephrology, Economics and Econometrics, Pathology and Forensic Medicine and Rheumatology, having authored 33 papers that have together received 1.1k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (12 papers), Advanced Causal Inference Techniques (8 papers), Statistical Methods in Clinical Trials (8 papers), Parathyroid Disorders and Treatments (6 papers), Vitamin D Research Studies (4 papers), Ethics in Clinical Research (3 papers), Pharmaceutical Economics and Policy (3 papers) and Respiratory and Cough-Related Research (2 papers). The work is most often cited by research in Statistics and Probability (138 citations), Nephrology (118 citations), Health Informatics (19 citations), Oncology (202 citations) and Pulmonary and Respiratory Medicine (231 citations). Frank Pétavy has collaborated with scholars based in Netherlands, Germany and United Kingdom. Frequent co-authors include Iman El‐Hariry, Guido Rasi, Marc‐Oliver Grimm, Uwe Treiber, Marco R. de Groot, D. J. Richel, Philippe Beuzeboc, Christian Wülfing, Roma Parikh and Jean‐Pascal Machiels. Their work appears in journals such as Clinical Pharmacology & Therapeutics, Statistics in Biopharmaceutical Research, Nature Reviews Drug Discovery, British Journal of Clinical Pharmacology and Nephrology Dialysis Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact